ONCOPOOL Consortium at Breast Institute, Nottingham City Hospital, NG5 1PB, UK.
Eur J Cancer. 2010 Jan;46(1):56-71. doi: 10.1016/j.ejca.2009.09.009.
ONCOPOOL is a retrospectively compiled database of primary operable invasive breast cancers treated in the 1990s in 10 European breast cancer Units. Sixteen thousand and nine hundred and forty four cases were entered, with tumours less than 5 cm diameter in women aged 70 or less (mean age 55).
Data were date of birth, mode of diagnosis, pathology (size, lymph node status, grade, type, lympho-vascular invasion and hormone receptor) and therapies and outcome measures: first local, regional or distant recurrences, contralateral primary, date and cause of death.
Mean diameter 1.8 cm, 66% lymph node negative, 24% 1-3 lymph nodes involved and 10% had 4 or more involved. Grade 1, 29%; Grade 2, 41%; and Grade 3, 30%. Polynomial relationships were established between grade, stage and size. Seventy-five percent were oestrogen receptor (ER) positive. ER closely related to grade.
Overall Survival was 89% at 5 years from diagnosis, 80% 10 years and 73% 15 years; Breast Cancer-Specific survivals were 91%, 84% and 79%. Survival strongly related to the Nottingham Prognostic Index (NPI). Cases detected at screening had 84% 10-year survival, those presenting symptomatically 76%. ER positive cases treated with adjuvant hormone therapy had a reduction in risk of death of 13% over those not receiving adjuvant therapy (p=0.000). ER negative cases treated with chemotherapy showed a risk reduction of 23% over those not receiving chemotherapy (p=0.000).
ONCOPOOL 是一个回顾性的数据库，包含了 20 世纪 90 年代在 10 个欧洲乳腺癌中心接受治疗的原发性可手术浸润性乳腺癌病例。共纳入了 16944 例患者，年龄均在 70 岁以下（平均年龄 55 岁），肿瘤直径小于 5cm。
数据包括出生日期、诊断方式、病理学特征（肿瘤大小、淋巴结状态、分级、类型、淋巴管血管侵犯和激素受体）以及治疗和结局指标：首次局部、区域或远处复发、对侧原发性乳腺癌、死亡日期和原因。
肿瘤平均直径为 1.8cm，66%的患者淋巴结阴性，24%的患者淋巴结 1-3 个转移，10%的患者淋巴结转移数≥4。分级为 1 级的占 29%，2 级的占 41%，3 级的占 30%。分级、分期和肿瘤大小之间建立了多项式关系。75%的患者雌激素受体（ER）阳性，ER 与分级密切相关。
诊断后 5 年的总生存率为 89%，10 年生存率为 80%，15 年生存率为 73%；乳腺癌特异性生存率分别为 91%、84%和 79%。生存与诺丁汉预后指数（NPI）密切相关。通过筛查发现的病例 10 年生存率为 84%，有症状就诊的病例为 76%。接受辅助激素治疗的 ER 阳性病例死亡风险降低了 13%（p=0.000），而未接受辅助激素治疗的病例死亡风险增加了 13%。接受化疗的 ER 阴性病例死亡风险降低了 23%（p=0.000）。
